Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 23, 2024
Product Development

Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals

The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients
BioCentury | Dec 14, 2016
Clinical News

Actimmune: Ph III STEADFAST data

BioCentury | May 30, 2016
Company News

Boehringer Ingelheim, Horizon Pharma deal

BioCentury | May 7, 2016
Financial News

ACT Genomics raises $12.5M series B

BioCentury | Jan 4, 2016
Clinical News

Actimmune interferon gamma-1b: Phase I started

BioCentury | Sep 14, 2015
Company News

Fox Chase Cancer Center, Horizon Pharma deal

BioCentury | Jun 22, 2015
Clinical News

Interferon gamma-1b: Phase III started

BioCentury | Apr 20, 2015
Clinical News

Actimmune interferon gamma-1b regulatory update

Items per page:
1 - 10 of 242